×
About 3,220 results

ALLMedicine™ Liver Tumors Center

Research & Reviews  1,168 results

A Retrospective Analysis of Clinical Characteristics, Treatment Modalities and Outcome ...
https://doi.org/10.1097/MPH.0000000000002472
Journal of Pediatric Hematology/oncology; Odaman Al I, Demirağ B et. al.

May 11th, 2022 - Hepatic hemangiomas (HH) are the most common vascular tumors of the liver. It is important to distinguish hemangiomas from malignant liver tumors. The patients 0 to 1 years old, were diagnosed with HH and followed up in the oncology outpatient cli...

Multiple endocrine neoplasia type 1 involving both the liver and lung: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088025
World Journal of Surgical Oncology; Lai J, Huang Y et. al.

May 11th, 2022 - Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant tumor syndrome with a high degree of heterogeneity in clinical phenotypes, generally involving the parathyroid, anterior pituitary, and enteropancreas. In recent years, severa...

Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by prov...
https://doi.org/10.1002/hep.32555
Hepatology (Baltimore, Md.); Liu JJ, Xin B et. al.

May 4th, 2022 - Shp2 is the first identified pro-oncogenic tyrosine phosphatase that acts downstream of receptor tyrosine kinases (RTK) to promote Ras-Erk signaling. However, this phosphatase was also shown to be anti-tumorigenic in hepatocellular cancer (HCC). T...

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER)
https://clinicaltrials.gov/ct2/show/NCT04573881

May 2nd, 2022 - This trial is a single arm, non-randomized prospective trial. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Subjects will then be followed for 30 day...

Does Preoperative Thrombocytopenia in Patients Undergoing Robotic Hepatectomy for Liver...
https://doi.org/10.1177/00031348221087919
The American Surgeon; Crowley M, Rayman S et. al.

Apr 27th, 2022 - Thrombocytopenia is a known surrogate marker for cirrhosis and portal hypertension and has been associated with increased risk of poor perioperative outcomes when studied in "open" operations. This study was undertaken to assess thrombocytopenia a...

see more →

Guidelines  1 results

Clinical practice guidelines for the management of liver metastases from extrahepatic p...
https://doi.org/10.1002/jhbp.868
Journal of Hepato-biliary-pancreatic Sciences; Yamamoto M, Yoshida M et. al.

Nov 18th, 2020 - Hepatectomy is standard treatment for colorectal liver metastases; however, it is unclear whether liver metastases from other primary cancers should be resected or not. The Japanese Society of Hepato-Biliary-Pancreatic Surgery therefore created cl...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  57 results

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER)
https://clinicaltrials.gov/ct2/show/NCT04573881

May 2nd, 2022 - This trial is a single arm, non-randomized prospective trial. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Subjects will then be followed for 30 day...

Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea
https://clinicaltrials.gov/ct2/show/NCT03586050

Apr 19th, 2022 - This prospective, single-arm single center study will provide clinical data for the Neuwave Medical Microwave Ablation System and accessories. Individuals who undergo microwave ablation of liver tumors who meet study entry criteria, will be enroll...

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00667628

Apr 15th, 2022 - Advanced metastatic hepatocellular carcinoma (HCC) is not treatable by surgical approaches or locoregional therapies such as hepatic artery hemoembolization or radiofrequency ablation (RFA) which are effective in controlling localized tumors. Tran...

EXALT: EXercise Attenuates Liver Tumors Trial
https://clinicaltrials.gov/ct2/show/NCT03979547

Mar 9th, 2022 - Primary liver cancer is the leading cause of cancer worldwide. The majority of primary liver cancers are hepatocellular carcinoma (HCC) and occur in the setting of cirrhosis of the liver. Body fat and systemic inflammation are determinants of HCC ...

Treat Primary and Metastatic Liver Tumors
https://clinicaltrials.gov/ct2/show/NCT05240040

Feb 15th, 2022 - A retrospective chart review of patients who have the diagnosis of intrahepatic cholangiocarcinoma. Only patients treated at MDMC are included and data will be obtained from Meditech and Epic. A non-identified database of cases with the diagnosis ...

see more →

News  44 results

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
https://www.onclive.com/view/administration-of-rp1-through-intratumoral-injection-offers-unique-advantages-in-melanoma-treatment

Apr 26th, 2022 - Oncolytic immunotherapy with talimogene laherparepvec (T-VEC; Imlygic) and vusolimogene oderparepvec (RP1) has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration, according to Nik...

Cetuximab–Radionuclide Functionalized Polymeric Nanocomplexes: A Radiopharmaceutical Perspective for Liver Cancer
https://www.onclive.com/view/cetuximab-radionuclide-functionalized-polymeric-nanocomplexes-a-radiopharmaceutical-perspective-for-liver-cancer

Mar 4th, 2022 - Liver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors. Therapeutic options for liver cancer treatment are very limited and the prognosis is poor. Patients get diagnosed at a late stage of liver cancer. Many...

AHN Cancer Institute Chair and Internationally Renowned Cancer Surgeon David L. Bartlett, MD, Opens Pittsburgh Office
https://www.onclive.com/view/ahn-cancer-institute-chair-and-internationally-renowned-cancer-surgeon-david-l-bartlett-md-opens-pittsburgh-office

Dec 2nd, 2021 - David L. Bartlett, MD, a renowned cancer researcher and clinician specializing in advanced surgical treatments for abdominal cancers, has reopened his Pittsburgh practice and will begin seeing patients at AHN Cancer Institute – Allegheny General o...

New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases
https://www.onclive.com/view/new-strategy-boosts-microenvironment-to-promote-antitumor-immunity-in-gi-metastases

Oct 6th, 2021 - Associate Professor, Surgery The University of Illinois at Chicago Chicago, IL Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal (GI) maligna...

Expert Shares Insight on Navigating Neuroendocrine Tumor Treatment
https://www.onclive.com/view/expert-shares-insight-on-navigating-neuroendocrine-tumor-treatment

Oct 6th, 2021 - Paul R. Helft, MD Since the FDA approval of Lutathera (lutetium Lu 177 dotatate) in January 2018, other treatments may take a backseat to peptide receptor radionuclide therapy (PRRT) for patients with gastroenteropancreatic (GEP)-neuroendocrine t...

see more →

Patient Education  1 results see all →